Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.
Highlighted PresentationsMitral valveStructural heart disease

SOLACI-SBHCI 2023 | Mitral Valve Interventions beyond the TEER Era: Time to Re-Evaluate Innovation Priorities?- Dr. Eberhard Grube

solaci
solaci
501
0

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress.

In this case, check the presentation by Dr. Eberhard Grube, entitled “Mitral Valve Interventions beyond the TEER Era: Time to Re-Evaluate Innovation Priorities?”

Eberhard-Grube-solaci-sbhci-2023

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
SOLACI-SBHCI 2023 | Alternative Vascular Access for Structural Heart Interventions – Dr. Diego Silveira da Costa
Next article
SOLACI-SBHCI 2023 | AORTIC ANEURYSM FROM THE GUIDELINES TO THE REAL WORLD – Dr. Felix Damas de los Santos
solaci
solaci

More articles by this author

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Dr. Juan Manuel Pérez - 0
Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

Dr. Juan Manuel Pérez - 0
The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

Dr. Andrés Rodríguez - 0
This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

Dr. Andrés Rodríguez - 0
The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Structural heart disease

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased...
Dr. Juan Manuel Pérez -
SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Dr. Juan Manuel Pérez - 0
Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

Dr. Juan Manuel Pérez - 0
The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

Dr. Andrés Rodríguez - 0
This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...